Novelion Therapeutics Inc. (NVLN)’s Financial Results Comparing With BioSpecifics Technologies Corp. (NASDAQ:BSTC)

We are contrasting Novelion Therapeutics Inc. (NASDAQ:NVLN) and BioSpecifics Technologies Corp. (NASDAQ:BSTC) on their profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation. They both are Biotechnology companies, competing one another.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Novelion Therapeutics Inc. 128.63M 0.14 113.47M -6.05 0.00
BioSpecifics Technologies Corp. 29.81M 15.63 16.51M 2.40 25.59

In table 1 we can see Novelion Therapeutics Inc. and BioSpecifics Technologies Corp.’s gross revenue, earnings per share and valuation.

Profitability

Table 2 has Novelion Therapeutics Inc. and BioSpecifics Technologies Corp.’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Novelion Therapeutics Inc. -88.21% 404.3% -32.6%
BioSpecifics Technologies Corp. 55.38% 21.8% 20.7%

Risk & Volatility

Novelion Therapeutics Inc. has a beta of 1.64 and its 64.00% more volatile than Standard & Poor’s 500. Competitively, BioSpecifics Technologies Corp. is 46.00% more volatile than Standard & Poor’s 500, because of the 1.46 beta.

Liquidity

The Current Ratio and a Quick Ratio of Novelion Therapeutics Inc. are 0.2 and 0.2. Competitively, BioSpecifics Technologies Corp. has 48.4 and 48.4 for Current and Quick Ratio. BioSpecifics Technologies Corp.’s better ability to pay short and long-term obligations than Novelion Therapeutics Inc.

Insider & Institutional Ownership

Novelion Therapeutics Inc. and BioSpecifics Technologies Corp. has shares owned by institutional investors as follows: 76.5% and 59.3%. Novelion Therapeutics Inc.’s share owned by insiders are 0.7%. Comparatively, 19.6% are BioSpecifics Technologies Corp.’s share owned by insiders.

Performance

In this table we provide the Week, Month, Quarter, Half Year, Year and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Novelion Therapeutics Inc. 18.8% 63.05% -71.25% -71.39% -67.14% -63.14%
BioSpecifics Technologies Corp. 0.07% -3.28% 5.15% 43.88% 42.55% 41.73%

For the past year Novelion Therapeutics Inc. had bearish trend while BioSpecifics Technologies Corp. had bullish trend.

Summary

BioSpecifics Technologies Corp. beats on 9 of the 11 factors Novelion Therapeutics Inc.

Novelion Therapeutics Inc., a biopharmaceutical company, develops a portfolio of therapies for individuals living with rare diseases. Its product portfolio includes MYALEPT (metreleptin), a recombinant analogue of human leptin, indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; and lomitapide hard capsule for the treatment of homozygous familial hypercholesterolemia in adults under the brand names of JUXTAPID and LOJUXTA. The companyÂ’s orphan drug-designated product candidate is zuretinol acetate, an oral synthetic retinoid, in late stage development for the treatment of inherited retinal disease caused by underlying mutations in retinal pigment epithelium protein 65 and lecithin: retinol acyltransferase genes. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States. The company offers injectable collagenase for the treatment of DupuytrenÂ’s contracture and PeyronieÂ’s disease under the XIAFLEX brand in Canada and Australia, as well as under XIAPEX brand name in Europe. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, and plantar fibromatosis, as well as for the treatment of human lipoma and uterine fibroids. The company is also involved in the development of other clinical indications for which collagenase injection has been tested, such as keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. It has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Lynbrook, New York.

"

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.